A LEGG Up Above the Competition
What is Deep Vein Thrombosis?
Deep Vein Thrombosis (DVT) is a medical condition that occurs when a blood clot forms in one of the deep veins in the body—typically located in the lower leg, thigh, pelvis, or occasionally the arm.
DVT is part of a broader category known as Venous Thromboembolism (VTE), which includes DVT and Pulmonary Embolism (PE)—a life-threatening complication that arises if a clot breaks off, travels through the bloodstream, and lodges in the lungs.
DVT is a silent killer — affecting millions globally, with over 80% of Americans unaware of the risk.
Up to 900,000 Americans are affected by VTE each year, encompassing both DVT and PE.
Between 60,000 and 100,000 people die each year in the U.S. as a result of VTE.
Tragically, one in four people who experience PE may die suddenly—often receiving no warning.
VTE is a leading cause of preventable hospital death and a major reason for unplanned readmissions—especially after surgery.
Disproportionate impact — Black individuals face a 30–60% higher risk than whites.
A personal mission — Inspired by a patient’s life-threatening DVT, Dr. Goodlett created The LEGG Buddy to close this gap.
https://www.cdc.gov/blood-clots/about/index.html
Discover The LEGG Buddy
Learn more about The LEGG Buddy
The Problem
Deep Vein Thrombosis (DVT) is a silent killer, affecting millions worldwide. Over 80% of Americans don’t know it exists, yet it can cause sudden, fatal complications. Black individuals face up to a 60% higher risk, highlighting urgent health disparities. Current solutions — drugs, compression devices, elastic hose — are often uncomfortable, risky, or inaccessible.
The Solution
The LEGG Buddy is a patent-pending, smart device that prevents and detects DVT through simple seated leg exercises and real-time blood flow monitoring. Paired with a connected app, it delivers instant feedback and early warnings — making prevention simple, affordable, and effective.
The Opportunity
$4.8B global DVT market projected to reach $8.4B by 2033
100M+ U.S. patients at risk annually, plus rehab centers, insurers & corporate wellness buyers
Unique competitive edge: comfort, affordability, monitoring, and prevention in one solution
Experienced team & roadmap to rapidly scale and capture market share
The Impact
The LEGG Buddy isn’t just a device — it’s a life-saving innovation with the potential to reduce preventable deaths and create substantial returns for investors.
About Dr. Goodlett
Dr. Garry M. Goodlett, M.D., Th.D. is a second-generation physician, lifelong learner, and medical inventor. Trained at the University of California, Meharry Medical College, and San Francisco General Hospital, he built a distinguished career in family medicine, practicing across urgent care, emergency medicine, and private practice, and founding an urgent care program for a major HMO.
Now retired, Dr. Goodlett continues to make an impact as a medical consultant and patient advocate. His dedication to innovation inspired the creation of The LEGG Buddy—a smart device designed to prevent and monitor deep vein thrombosis (DVT) while improving patient outcomes worldwide.
Dr. Goodlett’s determination to develop this solution was deeply personal. After witnessing a patient suffer a life-threatening DVT event, he committed himself to addressing this silent but devastating condition.
Awards and Recognition
University of Iowa John Pappajohn Entrepreneurial Center Venture School Semifinalist
Contact Us
We’re currently raising funds to bring The LEGG Buddy to market.
Contact us to learn more about investment opportunities.
A Letter from Dr. Goodlett
Dear Friends and Supporters,
After more than 40 years in family medicine, I’ve dedicated my retirement to solving one of healthcare’s silent killers: deep vein thrombosis (DVT). The LEGG Buddy is the result—a smart, affordable device that not only helps prevent blood clots, but also monitors patient health and reduces disparities in care.
We are now entering the next critical stage:
Finalizing product development
Securing FDA clearance and completing clinical trials
Launching our first marketing campaign
Pursuing NIH/NSF Phase I funding
To achieve these goals, we are seeking strategic partners and early investors who share our mission to save lives while addressing a $4.8B market projected to nearly double in the next decade.
If this vision resonates with you, I would be honored to connect and discuss how you can be part of this journey.
Sincerely,
Dr. Garry M. Goodlett, M.D., Th.D.